Cat. No. 2348
Alternative Name: GV 150526A
Chemical Name: 4,6-Dichloro-3-[(1E)-3-oxo-3-(pheny
Biological ActivityHighly potent and selective non-competitive antagonist acting at the strychnine-insensitive glycine binding site of the NMDA receptor-channel complex (Kd = 0.8 nM). Displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites. Orally bioavailable and active in vivo.
Licensing InformationSold with the permission of GlaxoSmithKline
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Kajbaf et al (2003) Pharmacokinetics, metabolism and excretion of the glycine antagonist GV150526A in rat and dog. Xenobiotica. 33 415. PMID: 12745876.
Mugnaini et al (2000) Receptor binding characteristics of the novel NMDA receptor glycine site antagonist [3H]GV150526A in rat cerebral cortical membranes. Eur.J.Pharmacol. 391 233. PMID: 10729363.
Di Fabio et al (1997) Substituted indole-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. J.Med.Chem. 40 841. PMID: 9083472.
If you know of a relevant reference for Gavestinel please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Gavestinel from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Gavestinel, supplier, Potent, selective, glycine, site, antagonists, Orally, available, active, vivo, Glutamate, NMDA, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, GV150526A, GlaxoSmithKline, GSK, Tocris Bioscience, NMDA Receptor Antagonist products